GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (WBO:TKD) » Definitions » ROE % Adjusted to Book Value

Takeda Pharmaceutical Co (WBO:TKD) ROE % Adjusted to Book Value : 6.53% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Takeda Pharmaceutical Co ROE % Adjusted to Book Value?

Takeda Pharmaceutical Co's ROE % for the quarter that ended in Dec. 2023 was 6.14%. Takeda Pharmaceutical Co's PB Ratio for the quarter that ended in Dec. 2023 was 0.94. Takeda Pharmaceutical Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 6.53%.


Takeda Pharmaceutical Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Takeda Pharmaceutical Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co ROE % Adjusted to Book Value Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 4.49 4.75

Takeda Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.02 1.88 5.32 -2.66 6.53

Competitive Comparison of Takeda Pharmaceutical Co's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's ROE % Adjusted to Book Value falls into.



Takeda Pharmaceutical Co ROE % Adjusted to Book Value Calculation

Takeda Pharmaceutical Co's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=5.04% / 1.06
=4.75%

Takeda Pharmaceutical Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=6.14% / 0.94
=6.53%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (WBO:TKD) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (WBO:TKD) Headlines

No Headlines